^
Association details:
| Biomarker: | ALK mutation |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Keytruda (pembrolizumab) (PD1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Published date:
07/17/2015
Excerpt:
Keytruda as monotherapy is indicated for the treatment of locally advanced or metastatic NSCLC in adults whose tumours express PD-L1 with a ≥ 1% TPS...Patients with EGFR or ALK positive tumour mutations should also have received targeted therapy before receiving Keytruda.
Source:
Excerpt:
Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving KEYTRUDA
Source:
Title:
Pembrolizumab with pemetrexed and platinum chemotherapy for untreated, metastatic, non-squamous non-small-cell lung cancer
Published date:
03/10/2021
Excerpt:
Pembrolizumab with pemetrexed and platinum chemotherapy is recommended as an option for untreated, metastatic, non squamous non-small-cell lung cancer (NSCLC) in adults whose tumours have no epidermal growth factor receptor (EGFR)‑positive or anaplastic lymphoma kinase (ALK)‑positive mutations.
Secondary therapy:
Chemotherapy
Source:
Title:
Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Patients With Untreated Metastatic Non–Small Cell Lung Cancer
Excerpt:
...Participants must meet all of the following inclusion criteria to be eligible for participation in this study (no waivers for participant eligibility will be permitted).1)Participants assigned male at birth and participants assigned female at birth, 18 years of age or older, able to understand and give written informed consent.2)Life expectancy ≥ 3 months.3)Pathologically documented NSCLC that meets both of the criteria below:a)Have documented evidence of Stage IV NSCLC disease at the time of enrollment (based on AJCC, Eighth Edition).b)Have documented negative test results for epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) mutations. ...
Trial ID:
Source:
Title:
immunotherapy alone versus immunotherapy-chemotherapy in first line treatment of lung cancer: which treatment works best?
Excerpt:
...In order to be eligible to participate in this study, a subject must meet all of the following criteria:• Histologically confirmed NSCLC, negative for EGFR and ALK mutations• WHO PS 0-2• No prior systemic therapy• High PD-L-1 expression (≥50% TPS)• High tumor burden (≥2 extrapulmonary metastases (M1c)) and not amenable for local consolidative therapies...
Trial ID:
More C2 evidence
Source:
Title:
Testing the Addition of an Experimental Medication MK-3475 (Pembrolizumab) to Usual Anti-Retroviral Medications in Patients With HIV and Cancer
Excerpt:
...patients that have actionable molecular targets (e.g., epidermal growth factor receptor [EGFR], anaplastic lymphoma kinase [ALK], c-ros oncogene 1[ROS1] mutations) must have received (when indicated) prior appropriate targeted therapy using Food and Drug Administration (FDA)-approved agents...
Trial ID:
Source:
Title:
Pembrolizumab Plus Pemetrexed for Elderly Patients With Non-Sq NSCLC With PD-L1 < 50%: CJLSG1901
Excerpt:
...Without activating mutation in EGFR or ALK chromosomal translocation....
Trial ID:
Source:
Title:
Efficacy Comparison of Dostarlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy in Participants with Metastatic Non squamous Non small Cell Lung Cancer
Excerpt:
...Participant has histologically- or cytologically-confirmed metastatic non-squamous NSCLC with documented absence of a sensitizing EGFR, ALK, ROS-1, or BRAF V600E mutation or other genomic aberration for which an approved targeted therapy is available.. ...
Trial ID:
